Clinical trials: Locally Advanced Rectal Cancer
Rectal Cancer
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design…
- Trial name
- NCT04443543
- Testing
- Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Fudan University
Rectal Cancer
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally…
- Trial name
- TRIUNITE-03 (NCT06718543)
- Testing
- AK112 with SCRT and CapeOX, AK112 with SCRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- fan li
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Locally Advanced Rectal Carcinoma
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This study analyzed the efficacy differences between neoadjuvant therapy and direct surgical treatment in patients with locally advanced rectal cancer in the real world.
- Trial name
- NCT06314737
- Volunteers
- 3,515 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Cancer, Rectal Adenocarcinoma
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and…
- Trial name
- NCT02935309
- Testing
- Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Rectal Cancer
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them even more severer.
- Trial name
- NCT02942563
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Colorectal Cancer
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from…
- Trial name
- NCT00066846
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- 33 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
Background: Neoadjuvant chemoradiotherapy (CRT) and total mesorectum excision (TME) has become the standard therapy for the treatment of locally advanced rectal cancer (LARC) to reduce the local recurrence rate, however, no…
- Trial name
- NCT03245203
- Testing
- FOLFIRI+beacizumab, CRT
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Rectal Cancer
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Preoperative induction chemotherapy has been successfully used in a variety of malignancies and provides several advantages over postoperative therapy.
- Trial name
- NCT00216086
- Testing
- Capecitabine, Irinotecan, EUS
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gabi Chiorean, MD
Rectal Cancer
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum).
- Trial name
- HDRBT (NCT01226979)
- Testing
- High-dose endorectal brachytherapy (HDRBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Advanced Rectal Cancer
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy.
- Trial name
- NCT05228431
- Testing
- XELOX, Capecitabine monotherapy, Radiation
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Zhen-Hai Lu
Cancer of the Rectum
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with…
- Trial name
- Néofirinox (NCT01804790)
- Testing
- mFolfirinox, Radiotherapy 50 Gy, Capecitabine
- Where
- 36 sites in France
- Volunteers
- 461 people
- Sponsor
- UNICANCER
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
- Trial name
- ShorTrip (NCT05253846)
- Testing
- Irinotecan, Oxaliplatin, Lederfolin
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Rectal Cancer
RadioPathomics Artificial Intelligence Model to Predict nCRT Response in Locally Advanced Rectal Cancer
In this study, investigators utilize a radiopathomics integrated Artificial Intelligence (AI) supportive system to predict tumor response to neoadjuvant chemoradiotherapy (nCRT) before its administration for patients with locally…
- Trial name
- RPAI-pCR (NCT04271657)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Adenocarcinoma
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a…
- Trial name
- PRELUDE (NCT07802197)
- Testing
- radiotherapy, surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Colorectal Cancer
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084773
- Testing
- cetuximab, fluorouracil, neoadjuvant therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center